RETRACTED: Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer

Mark S Duxbury; Hiromichi Ito; Eric Benoit; Michael J Zinner; Stanley W Ashley; Edward E Whang

doi:10.1016/j.surg.2004.04.029

RETRACTED: Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer

Surgery. 2004 Aug;136(2):261-9. doi: 10.1016/j.surg.2004.04.029.

Authors

Mark S Duxbury¹, Hiromichi Ito, Eric Benoit, Michael J Zinner, Stanley W Ashley, Edward E Whang

Affiliation

¹ Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

PMID: 15300189
DOI: 10.1016/j.surg.2004.04.029

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the Editors-in-Chief, because an investigation by Harvard Medical School and the Brigham and Women’s Hospital has concluded that Figure 1A is invalid and no underlying research data are available to resolve the discrepancies or validate the reported results.

Publication types

Retracted Publication

MeSH terms

Apoptosis
Cell Line, Tumor
Deoxycytidine / analogs & derivatives*
Deoxycytidine / pharmacology
Gemcitabine
Humans
Matrix Metalloproteinase 9 / genetics
NF-kappa B / metabolism
Pancreatic Neoplasms / pathology
Pancreatic Neoplasms / therapy*
RNA Interference*
Retroviridae / genetics
Ribonucleoside Diphosphate Reductase / antagonists & inhibitors*
Ribonucleoside Diphosphate Reductase / genetics

Substances

NF-kappa B
Deoxycytidine
ribonucleotide reductase M2
Ribonucleoside Diphosphate Reductase
Matrix Metalloproteinase 9
Gemcitabine